Takeda buys Abbott’s stake in TAP
Japanese drug maker Takeda will be the sole owner of TAP Pharmaceutical Products after the firm finalizes a deal March 19 to buy Abbott's share of the 50/50 joint venture. When the transaction closes, TAP will be integrated into Takeda Pharmaceuticals North America and Takeda Global Research & Development Center, with the two reporting to a newly established Takeda America Holdings. Takeda says the deal will make the company a top 15 pharmaceutical company in the U.S. As part of the deal, Abbott and Takeda will evenly divide the value of the joint venture, with Abbott maintaining the rights to the prostate cancer drug Lupron (leuprolide acetate). Takeda gets rights to the only other TAP-marketed product - the heartburn and gastro-esophageal reflux medication Prevacid (lansoprazole)
You may also be interested in...
Takeda made an aggressive move toward its goal of becoming a top three oncology company with the acquisition of Millennium for $8.8 billion
FDA’s Bumpus Will Be Principal Deputy Commissioner; Cosmetics Industry Reacts With Congratulations, Questions
Chief scientist Namandjé Bumpus will replace Janet Woodcock as principal deputy commissioner at the US FDA when the latter steps down in early 2024. The Personal Care Products Council says Bumpus will continue to lead MoCRA implementation efforts while a new chief scientist is sought, but those and other details remain fuzzy.
Private Company Edition: Lilly will open a third accelerator, this time in San Diego, and Fosun partnered with Treehill to help later-stage firms get over the finish line. Also, Flagship – after recent UK investments – signals its next fund will total $3bn. ArrivoBio and Alto Neuroscience raised $45m each.